Alkermes (ALKS) Stock Forecast & Price Target

Compare

547 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALKS Analyst Ratings

Moderate Buy

9 Buy

5 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Alkermes

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALKS Stock 12 Month Forecast

Average Price Target

$40.39

▲(41.97% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $40.39 with a high forecast of $54.00 and a low forecast of $26.13. The average price target represents a 41.97% change from the last price of $28.45.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","40":"$40","55":"$55","32.5":"$32.5","47.5":"$47.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.13</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,32.5,40,47.5,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.4,31.29230769230769,33.184615384615384,35.07692307692307,36.96923076923077,38.86153846153846,40.753846153846155,42.646153846153844,44.53846153846154,46.43076923076923,48.323076923076925,50.215384615384615,52.107692307692304,{"y":54,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.4,30.245384615384616,31.09076923076923,31.936153846153847,32.78153846153846,33.62692307692308,34.472307692307695,35.317692307692305,36.16307692307692,37.00846153846154,37.853846153846156,38.699230769230766,39.54461538461538,{"y":40.39,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.4,29.148461538461536,28.896923076923077,28.645384615384614,28.39384615384615,28.142307692307693,27.89076923076923,27.639230769230767,27.387692307692305,27.136153846153846,26.884615384615383,26.63307692307692,26.38153846153846,{"y":26.13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.83,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.76,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.53,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.98,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$54.00

Average Price Target$40.39

Lowest Price Target$26.13

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Douglas Tsao

H.C. Wainwright

$46

Hold

61.69%

Upside

Reiterated

09/09/25

Alkermes Hold Rating: Promising NT1 Data Amidst Competitive and Clinical Challenges

Jessica Fye

J.P. Morgan

$34→$35

Hold

23.02%

Upside

Reiterated

09/09/25

J.P. Morgan Sticks to Its Hold Rating for Alkermes (ALKS)Raising our YE25 price target to $35 from prior $34.

Irene Nattel

RBC Capital

$42

Hold

47.63%

Upside

Assigned

09/08/25

RBC Capital Sticks to Their Hold Rating for Alkermes (ALKS)

Marc Goodman

Leerink Partners

―

Hold

―

Reiterated

09/08/25

Alkermes narcolepsy data 'solid,' about as expected, says LeerinkAlkermes narcolepsy data 'solid,' about as expected, says Leerink

Jason Gerberry

Bank of America Securities

$33

Hold

15.99%

Upside

Reiterated

09/08/25

Cautious Hold Rating on Alkermes Amid Competitive Pressures and Mixed Data for ALKS2680

Paul Matteis

Stifel Nicolaus

$42

Buy

47.63%

Upside

Reiterated

09/08/25

Stifel Nicolaus Keeps Their Buy Rating on Alkermes (ALKS)

Joseph Thome

TD Cowen

$38

Buy

33.57%

Upside

Reiterated

09/08/25

TD Cowen Remains a Buy on Alkermes (ALKS)

Uy Ear

Mizuho Securities

$40

Buy

40.60%

Upside

Reiterated

09/08/25

Promising Clinical Results and Market Potential Drive Buy Rating for AlkermesWe like ALKS, as we are bullish on alixorexton. We believe alixorexton has the potential to be best-in-class, with first-mover advantages in narcolepsy type II and idiopathic hypersomnia, in a new therapeutic category that will likely disrupt the >$10B sleep disorder landscape. Additionally, our valuation for the base business takes into consideration that consensus sales forecast may be high for the three core products - Vivitrol, Aristada, and Lybalvi.

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

$44

Buy

54.66%

Upside

Initiated

09/03/25

Wells Fargo Initiates a Buy Rating on Alkermes (ALKS)Wells Fargo initiates coverage on Alkermes (NASDAQ: ALKS) with a Overweight rating and a price target of $44.00.

David Amsellem

Piper Sandler

$38

Buy

33.57%

Upside

Reiterated

08/18/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Alkermes (NASDAQ: ALKS), Staar Surgical (NASDAQ: STAA) and Arvinas Holding Company (NASDAQ: ARVN)

Ami Fadia

Needham

$45

Buy

58.17%

Upside

Reiterated

07/29/25

Alkermes' Strong Q2 2025 Performance and Future Growth Potential Justify Buy Rating

Akash Tewari

Jefferies

$50→$54

Buy

89.81%

Upside

Reiterated

07/22/25

Alkermes price target raised to $54 from $50 at JefferiesAlkermes price target raised to $54 from $50 at Jefferies

Andrea Newkirk

Goldman Sachs

$26.13

Buy

-8.15%

Downside

Initiated

07/15/25

Alkermes: Promising Growth with Established Neuropsychological Portfolio and Emerging Orexin Agonist Opportunities

Ashwani Verma

UBS

$33→$42

Buy

47.63%

Upside

Upgraded

06/17/25

Analysts Conflicted on These Healthcare Names: Roche Holding AG (Other OTC: RHHVF) and Alkermes (NASDAQ: ALKS)

Charles Duncan

Cantor Fitzgerald

$43

Buy

51.14%

Upside

Reiterated

05/11/25

Cantor Fitzgerald Remains a Buy on Alkermes (ALKS)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Douglas Tsao

H.C. Wainwright

$46

Hold

61.69%

Upside

Reiterated

09/09/25

Alkermes Hold Rating: Promising NT1 Data Amidst Competitive and Clinical Challenges

Jessica Fye

J.P. Morgan

$34→$35

Hold

23.02%

Upside

Reiterated

09/09/25

J.P. Morgan Sticks to Its Hold Rating for Alkermes (ALKS)Raising our YE25 price target to $35 from prior $34.

Irene Nattel

RBC Capital

$42

Hold

47.63%

Upside

Assigned

09/08/25

RBC Capital Sticks to Their Hold Rating for Alkermes (ALKS)

Marc Goodman

Leerink Partners

―

Hold

―

Reiterated

09/08/25

Alkermes narcolepsy data 'solid,' about as expected, says LeerinkAlkermes narcolepsy data 'solid,' about as expected, says Leerink

Jason Gerberry

Bank of America Securities

$33

Hold

15.99%

Upside

Reiterated

09/08/25

Cautious Hold Rating on Alkermes Amid Competitive Pressures and Mixed Data for ALKS2680

Paul Matteis

Stifel Nicolaus

$42

Buy

47.63%

Upside

Reiterated

09/08/25

Stifel Nicolaus Keeps Their Buy Rating on Alkermes (ALKS)

Joseph Thome

TD Cowen

$38

Buy

33.57%

Upside

Reiterated

09/08/25

TD Cowen Remains a Buy on Alkermes (ALKS)

Uy Ear

Mizuho Securities

$40

Buy

40.60%

Upside

Reiterated

09/08/25

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

$44

Buy

54.66%

Upside

Initiated

09/03/25

Wells Fargo Initiates a Buy Rating on Alkermes (ALKS)Wells Fargo initiates coverage on Alkermes (NASDAQ: ALKS) with a Overweight rating and a price target of $44.00.

David Amsellem

Piper Sandler

$38

Buy

33.57%

Upside

Reiterated

08/18/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Alkermes (NASDAQ: ALKS), Staar Surgical (NASDAQ: STAA) and Arvinas Holding Company (NASDAQ: ARVN)

Ami Fadia

Needham

$45

Buy

58.17%

Upside

Reiterated

07/29/25

Alkermes' Strong Q2 2025 Performance and Future Growth Potential Justify Buy Rating

Akash Tewari

Jefferies

$50→$54

Buy

89.81%

Upside

Reiterated

07/22/25

Alkermes price target raised to $54 from $50 at JefferiesAlkermes price target raised to $54 from $50 at Jefferies

Andrea Newkirk

Goldman Sachs

$26.13

Buy

-8.15%

Downside

Initiated

07/15/25

Alkermes: Promising Growth with Established Neuropsychological Portfolio and Emerging Orexin Agonist Opportunities

Ashwani Verma

UBS

$33→$42

Buy

47.63%

Upside

Upgraded

06/17/25

Analysts Conflicted on These Healthcare Names: Roche Holding AG (Other OTC: RHHVF) and Alkermes (NASDAQ: ALKS)

Charles Duncan

Cantor Fitzgerald

$43

Buy

51.14%

Upside

Reiterated

05/11/25

Cantor Fitzgerald Remains a Buy on Alkermes (ALKS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alkermes

1 Month

xxx

Success Rate

11/17 ratings generated profit

Average Return

+4.55%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +4.55% per trade.

3 Months

xxx

Success Rate

14/17 ratings generated profit

Average Return

+6.90%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 82.35% of your transactions generating a profit, with an average return of +6.90% per trade.

1 Year

Paul MatteisStifel Nicolaus

Success Rate

14/17 ratings generated profit

Average Return

+20.41%

reiterated a buy rating 2 days ago

Copying Paul Matteis's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +20.41% per trade.

2 Years

xxx

Success Rate

17/20 ratings generated profit

Average Return

+13.00%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 85.00% of your transactions generating a profit, with an average return of +13.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALKS Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALKS has received 25 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. ALKS average Analyst price target in the past 3 months is 40.39.

Each month's total comprises the sum of three months' worth of ratings.

ALKS Financial Forecast

ALKS Earnings Forecast

Next quarter’s earnings estimate for ALKS is $0.40 with a range of $0.29 to $0.53. The previous quarter’s EPS was $0.67. ALKS beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.08% of the time in the same period. In the last calendar year ALKS has Outperformed its overall industry.

ALKS Sales Forecast

Next quarter’s sales forecast for ALKS is $355.28M with a range of $340.50M to $369.00M. The previous quarter’s sales results were $390.66M. ALKS beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.27% of the time in the same period. In the last calendar year ALKS has Outperformed its overall industry.

ALKS Stock Forecast FAQ

What is ALKS’s average 12-month price target, according to analysts?

Based on analyst ratings, Alkermes’s 12-month average price target is 40.39.

What is ALKS’s upside potential, based on the analysts’ average price target?

Alkermes has 41.97% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALKS a Buy, Sell or Hold?

Alkermes has a consensus rating of Moderate Buy which is based on 9 buy ratings, 5 hold ratings and 0 sell ratings.

What is Alkermes’s price target?

The average price target for Alkermes is 40.39. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $54.00 ,the lowest forecast is $26.13. The average price target represents 41.97% Increase from the current price of $28.45.

What do analysts say about Alkermes?

Alkermes’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of ALKS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Alkermes (ALKS) Stock Forecast & Price Target

ALKS Analyst Ratings

ALKS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alkermes

ALKS Analyst Recommendation Trends

ALKS Financial Forecast

ALKS Earnings Forecast

ALKS Sales Forecast

ALKS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts